Fargesin improves lipid and glucose metabolism in 3T3-L1 adipocytes and high-fat diet-induced obese mice

Biofactors. 2012 Jul-Aug;38(4):300-8. doi: 10.1002/biof.1022. Epub 2012 Jun 2.

Abstract

This study examined the effects of fargesin, a neolignan isolated from Magnolia plants, on obesity and insulin resistance and the possible mechanisms involved in these effects in 3T3-L1 adipocytes and high-fat diet (HFD)-induced obese mice. Fargesin promoted the glucose uptake in 3T3-L1 adipocytes. In HFD-induced obese mice, fargesin decreased the body weight gain, white adipose tissue (WAT), and plasma triglyceride, non-esterified fatty acid and glucose levels, and improved the glucose tolerance. Fargesin increased glucose transporter 4 (GLUT4) protein expression and phosphorylation of Akt, AMP-activated protein kinase (AMPK), and acetyl-CoA carboxylase (ACC) in both 3T3-L1 adipocytes and WAT of HFD-induced obese mice. Fargesin also decreased the mRNA expression levels of fatty acid oxidation-related genes, such as peroxisome proliferator-activated receptor α (PPARα), carnitine palmitoyltransferase-1 (CPT-1), uncoupling protein-2 (UCP-2) and leptin in WAT. Taken together, the present findings suggest that fargesin improves dyslipidemia and hyperglycemia by activating Akt and AMPK in WAT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3-L1 Cells
  • Acetyl-CoA Carboxylase / metabolism
  • Adenylate Kinase / metabolism
  • Adipocytes / drug effects
  • Adipocytes / metabolism
  • Animals
  • Benzodioxoles / pharmacology*
  • Benzodioxoles / therapeutic use
  • Blood Glucose
  • Diet, High-Fat / adverse effects*
  • Gene Expression / drug effects
  • Glucose / metabolism*
  • Glucose Transporter Type 4 / metabolism
  • Hypoglycemic Agents / pharmacology*
  • Hypoglycemic Agents / therapeutic use
  • Hypolipidemic Agents / pharmacology*
  • Hypolipidemic Agents / therapeutic use
  • Lignans / pharmacology*
  • Lignans / therapeutic use
  • Lipid Metabolism / drug effects*
  • Lipids / blood
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Obese
  • Obesity / drug therapy
  • Obesity / etiology
  • Obesity / metabolism*
  • Organ Size / drug effects
  • Phosphorylation
  • Protein Processing, Post-Translational
  • Proto-Oncogene Proteins c-akt / metabolism
  • Weight Gain / drug effects

Substances

  • Benzodioxoles
  • Blood Glucose
  • Glucose Transporter Type 4
  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • Lignans
  • Lipids
  • Slc2a4 protein, mouse
  • Proto-Oncogene Proteins c-akt
  • Adenylate Kinase
  • Acetyl-CoA Carboxylase
  • fargesin
  • Glucose